Tags

Type your tag names separated by a space and hit enter

Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors.
Int J Mol Sci. 2021 Feb 28; 22(5)IJ

Abstract

Adenovirus-based gene transfer vectors are the most frequently used vector type in gene therapy clinical trials to date, and they play an important role as genetic vaccine candidates during the ongoing SARS-CoV-2 pandemic. Immediately upon delivery, adenovirus-based vectors exhibit multiple complex vector-host interactions and induce innate and adaptive immune responses. This can severely limit their safety and efficacy, particularly after delivery through the blood stream. In this review article we summarize two strategies to modulate Ad vector-induced immune responses: extensive genomic and chemical capsid modifications. Both strategies have shown beneficial effects in a number of preclinical studies while potential synergistic effects warrant further investigations.

Authors+Show Affiliations

Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University (UW/H), Stockumer Str. 10, 58448 Witten, Germany.Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University (UW/H), Stockumer Str. 10, 58448 Witten, Germany.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33670859

Citation

Kreppel, Florian, and Claudia Hagedorn. "Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors." International Journal of Molecular Sciences, vol. 22, no. 5, 2021.
Kreppel F, Hagedorn C. Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. Int J Mol Sci. 2021;22(5).
Kreppel, F., & Hagedorn, C. (2021). Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. International Journal of Molecular Sciences, 22(5). https://doi.org/10.3390/ijms22052417
Kreppel F, Hagedorn C. Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. Int J Mol Sci. 2021 Feb 28;22(5) PubMed PMID: 33670859.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. AU - Kreppel,Florian, AU - Hagedorn,Claudia, Y1 - 2021/02/28/ PY - 2021/01/31/received PY - 2021/02/24/revised PY - 2021/02/24/accepted PY - 2021/3/6/entrez PY - 2021/3/7/pubmed PY - 2021/3/19/medline KW - HPMA KW - PEGylation KW - adenovirus KW - cloaking KW - immune response KW - shielding KW - stealthing KW - vector JF - International journal of molecular sciences JO - Int J Mol Sci VL - 22 IS - 5 N2 - Adenovirus-based gene transfer vectors are the most frequently used vector type in gene therapy clinical trials to date, and they play an important role as genetic vaccine candidates during the ongoing SARS-CoV-2 pandemic. Immediately upon delivery, adenovirus-based vectors exhibit multiple complex vector-host interactions and induce innate and adaptive immune responses. This can severely limit their safety and efficacy, particularly after delivery through the blood stream. In this review article we summarize two strategies to modulate Ad vector-induced immune responses: extensive genomic and chemical capsid modifications. Both strategies have shown beneficial effects in a number of preclinical studies while potential synergistic effects warrant further investigations. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/33670859/Capsid_and_Genome_Modification_Strategies_to_Reduce_the_Immunogenicity_of_Adenoviral_Vectors_ L2 - https://www.mdpi.com/resolver?pii=ijms22052417 DB - PRIME DP - Unbound Medicine ER -